Statistics such as the mean difference (MD), standardized mean difference (SMD), relative risk (RR), odds ratio (OR), hazard ratio (HR), and others are meant to be examined along with their 95% confidence intervals (CIs), and their significance can be understood by viewing these CIs as compatibility intervals. The 95% CIs around the MD and SMD are easily understood because they are expressed along a linear scale. The 95% CIs around the RR, OR, and HR are harder to understand because they are expressed along an exponential scale; however, when the numbers are log-transformed, they are linearized, and understanding becomes easy. Another approach to understanding the CIs around the RR, OR, or HR is to examine the reciprocal of the lower limit of the CI; however, because the reciprocal also lies along an exponential scale, this method is inferior to the log-transformation method. These approaches may seem daunting, but the difficulty is an illusion because log transformation or reciprocal transformation takes only a few seconds when a statistical calculator is opened. All terms and concepts are explained with extreme simplification and with the help of examples.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4088/JCP.23f14933 | DOI Listing |
J Ovarian Res
January 2025
Department of Medical Genetics, National Taiwan University Hospital, 19F, No. 8, Chung-Shan South Road, Taipei City, Taiwan.
Background: The homologous recombination deficiency (HRD) test is an important tool for identifying patients with epithelial ovarian cancer (EOC) benefit from the treatment with poly(adenosine diphosphate-ribose) polymerase inhibitor (PARPi). Using whole exome sequencing (WES)-based platform can provide information of gene mutations and HRD score; however, the clinical value of WES-based HRD test was less validated in EOC.
Methods: We enrolled 40 patients with EOC in the training cohort and 23 in the validation cohort.
BMC Pharmacol Toxicol
January 2025
Medical Surgical Nursing, Department of Nursing, School of Nursing and Midwifery, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Background: The global dissemination of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKp) poses a critical threat to public health. However, comprehensive data on the prevalence and resistance rates of CR-hvKp are limited. This systematic review and meta-analysis aim to estimate the pooled prevalence of carbapenem resistance among hvKp strains and assess the distribution of carbapenemase genes.
View Article and Find Full Text PDFBMC Health Serv Res
January 2025
Department of Health Services, Epidemiology and Disease Control Division, Ministry of Health and Population, Kathmandu, Nepal.
Background: The global elimination of leprosy transmission by 2030 is a World Health Organization (WHO) target. Nepal's leprosy elimination program depends on early case diagnosis and the performance of health workers and facilities. The knowledge and skills of paramedical staff (Leprosy Focal Person, LFP) and case documentation and management by health facilities are therefore key to the performance of health care services.
View Article and Find Full Text PDFJ Pharm Health Care Sci
January 2025
Department of Pharmacy, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto city, Kumamoto, 860-8556, Japan.
Background: Cataract surgeries are increasing annually, making appropriate medical management essential. The routine use of systemic antimicrobial agents for preventing surgical site infections lacks strong evidence and may increase the risk of drug-resistant bacteria and adverse events. This study examined the impact of discontinuing cefazolin (CEZ) administration during the perioperative period of cataract surgery on the incidence of postoperative adverse events and medical costs.
View Article and Find Full Text PDFJ Ovarian Res
January 2025
Department of Health Education, Nanjing Municipal Center for Disease Control and Prevention, No.3, Zizhulin Road, Nanjing, Jiangsu Province, 210003, China.
Background: PARP inhibitors (PARPis) have shown promising effectiveness for ovarian cancer. This network meta-analysis (PROSPERO registration number CRD42024503390) comprehensively evaluated the effectiveness and safety of PARPis in platinum-sensitive recurrent ovarian cancer (PSROC).
Methods: Articles published before January 6, 2024 were obtained from electronic databases.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!